Back to search

Article

Early Noninvasive Tracking of Response to Targeted Therapy in Non-Small Cell Lung Cancer

2024-06-11

Abstract excerpt

<title>Abstract</title> <p>There has been a longstanding need to develop improved methods for the rapid detection of response to anti-cancer therapies. Circulating tumor DNA based liquid biopsies allow for longitudinal monitoring of response to treatment. In this report, we analyzed plasma samples of 25 patients with advanced non-small cell lung cancer and observed that molecular responders had changes in circula...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
150448db-fde3-5202-a47d-38e6dff5df57
DOI
10.21203/rs.3.rs-4383235/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Early Noninvasive Tracking of Response to Targeted Therapy in Non-Small Cell Lung CancerDOI 10.21203/rs.3.rs-4383235/v1
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.Semantic proximity
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Semantic proximity
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.Semantic proximity
Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.Semantic proximity
Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the diseaseSemantic proximity
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib responseSemantic proximity
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung CancerSemantic proximity
Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patientsSemantic proximity
Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity
Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity
Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.Semantic proximity
A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutationsSemantic proximity
Select a neighboring publication to make it the new centre.